Hypercoagulability is a condition in which your blood clots more easily or more often than it should. Normally, clotting is a protective response that stops bleeding after an injury. In a hypercoagulable state, that balance tips too far toward clot formation, raising the risk of dangerous clots in veins or arteries. The condition can be inherited, acquired through other health conditions, or both.
How Blood Clots Form in the First Place
Blood clotting depends on a careful balance between proteins that promote clotting and proteins that prevent it. When the ratio of clot-promoting factors to clot-inhibiting factors increases, so does the risk of forming a clot where one isn’t needed. A 19th-century physician named Rudolf Virchow identified three conditions that set the stage for abnormal clotting, and this framework is still used today.
The first is damage to the blood vessel wall. Healthy vessel walls have a natural anticoagulant surface. When that lining is damaged, whether by inflammation, infection, or plaque buildup, the raw tissue underneath is exposed to flowing blood, triggering platelet activation and clot formation.
The second is sluggish or stagnant blood flow. When blood pools or slows down, clotting proteins and blood cells concentrate near the vessel wall instead of flowing past it. This is why sitting for long flights, extended bed rest after surgery, or anything that keeps your legs still for hours raises clot risk.
The third is the blood itself being in a hypercoagulable state, meaning it carries too many clot-promoting factors or too few natural anticoagulants. This is the component most people mean when they use the word hypercoagulability.
Inherited Causes
Some people are born with genetic variants that shift their clotting balance. The most common inherited thrombophilia is Factor V Leiden, a mutation that makes one of the body’s key clotting proteins resistant to being switched off. It appears in about 4 to 5 percent of the general population. People who carry one copy of the mutation have a moderately increased clot risk; those rare individuals who inherit two copies (roughly 1 in 5,000 people) face a much higher risk.
Another common variant is the prothrombin gene mutation (G20210A), which causes the body to produce about a third more prothrombin, a protein that helps clots solidify. Having prothrombin levels just 15 percent above normal doubles the risk of a venous clot, and this mutation pushes levels well beyond that threshold. The result is a two- to four-fold increase in clot risk. It’s found in 1 to 8 percent of healthy Europeans and up to 17 percent of those who have already had a clot.
Rarer inherited conditions involve deficiencies in the body’s natural anticoagulants: protein C, protein S, and antithrombin. Protein C deficiency occurs in roughly 0.2 to 0.4 percent of the population and raises the risk of a first venous clot about three-fold. Protein S deficiency is found in about 0.2 percent. Antithrombin deficiency is the rarest, affecting around 0.02 percent, but carries approximately a five-fold increase in clot risk based on retrospective data. People with any of these deficiencies may experience their first clot at a younger age than typical.
Acquired Causes
Many conditions that develop during life can push blood toward a hypercoagulable state. These acquired causes are actually more common than inherited ones, and they frequently overlap with genetic risk factors to compound the danger.
Antiphospholipid syndrome is one of the most significant acquired thrombophilias. It’s an autoimmune condition in which the body produces antibodies that activate the lining of blood vessels, platelets, and immune cells. These antibodies also interfere with natural anticoagulant pathways, including the protein C system, creating a strongly pro-clotting environment. Antiphospholipid syndrome can occur on its own or alongside lupus.
Cancer is another major acquired risk factor. Tumors release substances that activate the clotting system, and cancer treatments including surgery, chemotherapy, and prolonged immobility during recovery all add to the risk. Pregnancy shifts clotting balance as well, because the body naturally increases clotting factors to prepare for delivery. Smoking, obesity, and inflammatory diseases round out the list of common acquired contributors.
Hormonal Contraceptives and Clot Risk
Combined oral contraceptives containing estrogen deserve special mention because they’re used by millions of women and their effect on clotting is well documented. Overall, combined pills increase the risk of venous thromboembolism roughly three- to four-fold compared to not using hormonal contraception. In absolute terms, the background rate for young women not on contraception is about 1.9 to 3.7 clot events per 10,000 women per year, so even a four-fold increase translates to a small absolute number for most women.
The type of progestin in the pill matters. Older formulations containing levonorgestrel roughly quadruple clot risk, while newer pills containing desogestrel carry about a seven-fold increase and those with cyproterone acetate about a seven-fold increase as well. Women who have an underlying inherited thrombophilia on top of contraceptive use face a compounded risk that can become clinically significant.
Signs That a Clot Has Formed
Hypercoagulability itself doesn’t produce symptoms. You won’t feel it until a clot actually develops. The two most common and dangerous consequences are deep vein thrombosis (DVT) and pulmonary embolism (PE).
A DVT typically occurs in a leg and causes swelling, pain, warmth, and sometimes visible dilation of surface veins. The affected leg may appear slightly larger than the other. A PE happens when a clot breaks free and travels to the lungs, where it blocks blood flow. PE symptoms include sudden shortness of breath, chest pain (often sharp and worse with deep breaths), rapid heart rate, coughing up blood, and in severe cases, fainting or dangerously low blood pressure. A PE can be life-threatening and requires emergency treatment.
How Hypercoagulability Is Diagnosed
If a clot is suspected, the initial workup usually involves a clinical risk score combined with a blood test called D-dimer, which measures a byproduct of clot breakdown. A low-risk score with a negative D-dimer generally rules out a clot without further imaging. If the probability is moderate or high, or if the D-dimer is elevated, imaging follows. Compression ultrasound is the standard first-line test for suspected DVT, while CT pulmonary angiography is the preferred tool for detecting a PE.
Testing for the underlying hypercoagulable state itself is a separate question. Genetic tests for Factor V Leiden and the prothrombin mutation, along with antibody tests for antiphospholipid syndrome, can be done at any time. But tests for protein C, protein S, antithrombin, and certain lupus anticoagulant assays are affected by active clotting and by anticoagulant medications, so they shouldn’t be run during an acute clot event or during the first three months of anticoagulant treatment.
Current guidelines are selective about who should be tested. Thrombophilia testing isn’t recommended after a clot that had a clear trigger (like surgery or a long flight), because the treatment plan wouldn’t change. Even after an unprovoked clot, testing is generally reserved for situations where the results would actually alter a treatment decision, such as whether to continue blood thinners long-term. Routine screening of healthy family members, even those with a relative who has a known mutation, is not recommended unless a specific clinical decision (like whether to use estrogen-containing contraception) hinges on the result.
Treatment and Long-Term Management
When a clot develops in someone with hypercoagulability, the primary treatment is anticoagulant therapy. Direct oral anticoagulants (DOACs) have largely replaced warfarin as the first-line option because they perform equally well at preventing recurrent clots and strokes while being easier to manage. They don’t require routine blood monitoring or the dietary restrictions that warfarin demands.
Initial treatment typically involves a higher dose for the first one to three weeks, then a standard maintenance dose for at least three to six months. After that period, some people step down to a lower preventive dose that maintains protection against recurrence without significantly increasing bleeding risk. The decision about how long to continue treatment depends on whether the clot was provoked by a temporary risk factor or appeared without an obvious cause, and on the individual’s overall bleeding risk.
Early mobilization after a clot is encouraged rather than prolonged bed rest, which was once the standard advice. Getting moving again safely helps recovery and does not increase the risk of complications.
Post-Thrombotic Syndrome
One important long-term consequence of DVT that many people don’t hear about is post-thrombotic syndrome. It develops in 20 to 50 percent of people after a clot in a major leg vein, causing chronic swelling, pain, heaviness, and sometimes skin changes or ulcers in the affected leg. The clot damages the valves inside the vein, so blood doesn’t flow back toward the heart as efficiently.
The single most effective way to prevent post-thrombotic syndrome is proper anticoagulation during and after the acute clot. Compression stockings may help manage symptoms during the acute phase, though their role in long-term prevention is debated. For people with extensive clots in the upper leg veins who are at low bleeding risk, catheter-based procedures to physically remove or dissolve the clot may reduce the severity of post-thrombotic syndrome, but this approach is reserved for select cases.